|Bid||13.28 x 800|
|Ask||13.29 x 800|
|Day's Range||12.95 - 13.34|
|52 Week Range||8.27 - 17.62|
|Beta (3Y Monthly)||1.74|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.80|
CRANBURY, N.J., April 25, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 8,.
CRANBURY, N.J., April 15, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced the company will present initial preclinical data from its investigational adeno-associated.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a small-cap stock with a market capitalization of US$3.1b. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a k...
Amicus Therapeutics, Inc. (NASDAQ: FOLD ) has an extensive portfolio of novel therapies for rare diseases with a focus on lysosomal storage disorders, according to Janney Montgomery Scott. The Analyst ...
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, March 29, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Amicus Therapeutics (FOLD) today announced that the United States Patent and Trademark Office has issued two new patents directed to the composition of matter and methods of making ATB200, a unique recombinant human acid alpha-glucosidase (rhGAA) enzyme with optimized carbohydrate structures, particularly mannose-6 phosphate (M6P), to enhance uptake. ATB200 is the biologic component of the Company’s investigational Pompe treatment paradigm AT-GAA, which consists of ATB200 co-administered with AT2221, a pharmacological chaperone.
came up Wednesday night in the "Lightning Round" of Jim Cramer's entertaining and informative Mad Money program. Cramer said, "I think this one is really good. On-Balance-Volume (OBV) line turned stronger in late December.
The latest earnings announcement Amicus Therapeutics, Inc. (NASDAQ:FOLD) released in December 2018 confirmed that losses became smaller relative to the prior year's level as a result of recent tailwinds BelowRead More...
Continued Strong Galafold Launch Trends in Early 2019 - On Track to Achieve FY19 Revenue Guidance of $160M-$180M FY18 Galafold Revenue of $91.2M Reflects 650+ Fabry Patients.
NEW YORK, NY / ACCESSWIRE / February 28, 2019 / Amicus Therapeutics, Inc. (NASDAQ: FOLD ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 28, 2019 ...
In another boost to Philadelphia’s standing as a cell and gene therapy hub, Cranbury, New Jersey-based Amicus Therapeutics said Tuesday it is establishing a new global research and gene therapy center at uCity Square, where the company expects to have 200 employees over the next few years. Amicus will occupy the top three floors — a total of 75,000-square-foot — at the new University City Science Center building at 3675 Market Street. An initial group of a couple dozen company employees has already moved into temporary space within the same complex at BioLabs@CIC Philadelphia.
Amicus Therapeutics (FOLD) today announced it is establishing a new Global Research and Gene Therapy Center of Excellence in uCity Square in Philadelphia, PA, to advance its commitment to world-class science that makes a meaningful difference in the lives of people living with rare metabolic diseases. Philadelphia is a well-regarded ecosystem for biotechnology and gene therapy research and offers an ideal environment for Amicus to advance its pipeline, attract and retain top talent and foster external collaborations within the rare diseases.
Amicus Therapeutics (FOLD) today announced that the U.S. Food and Drug Administration (FDA) has granted to Amicus a Breakthrough Therapy Designation (“BTD”) to AT-GAA for the treatment of late onset Pompe disease, an inherited lysosomal storage disorder caused by the deficiency of an enzyme known as acid alpha-glucosidase (GAA). AT-GAA is the first ever investigational product for Pompe disease to receive BTD.
Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
CRANBURY, N.J., Feb. 12, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, February.
Zoetis Inc. (ZTS) is gearing up to report fourth-quarter 2018 results. The company continues to strengthen its diverse product portfolio through lifecycle innovations, strong customer relationships, and access to new markets and technologies.